Gene therapy for coronary heart disease

Journal of Internal Medicine

Volumn 250, Issue 5, 2001, Pages 367-368

  Yla Herttuala S ^a   Virtanen, A I ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR;

ADENOVIRUS; ANGINA PECTORIS; ANGIOGENESIS; CLINICAL TRIAL; DEVICE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENDOTHELIUM CELL; GALACTORRHEA; GENE THERAPY; HEART LEFT VENTRICLE; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

CORONARY DISEASE; GENE THERAPY; HUMANS;

EID: 0034772035     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00909.x     Document Type: Editorial

References (12)

1. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
2. Cardiovascular gene therapy
3. Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb - On the way to the clinic
4. VEGF gene delivery to muscle: Potential role for vasculogenesis in adults
5. 165 as sole therapy in patients with refractory coronary artery disease - 12-Month follow-up
6. Gene therapy for myocardial angiogenesis initial clinical results with direct myocardial injection of phVEGF (165) as sole therapy for myocardial ischaemia
7. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease
8. Angiogenesis gene therapy phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
9. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery. Results of a phase I randomised, double-blind, placebo-controlled trial
10. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
11. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor: The VIVA trial
12. Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia